{"original": "We reviewed 26 studies with 27 treatment groups that enrolled a total of 4893 participants. Twenty five of the studies were case series or uncontrolled long-term trial continuations, the other was an RCT comparing two opioids. Opioids were administered orally (number of study treatments groups [abbreviated as \"k\"] = 12, n = 3040), transdermally (k = 5, n = 1628), or intrathecally (k = 10, n = 231). Many participants discontinued due to adverse effects (oral: 22.9% [95% confidence interval (CI): 15.3% to 32.8%]; transdermal: 12.1% [95% CI: 4.9% to 27.0%]; intrathecal: 8.9% [95% CI: 4.0% to 26.1%]); or insufficient pain relief (oral: 10.3% [95% CI: 7.6% to 13.9%]; intrathecal: 7.6% [95% CI: 3.7% to 14.8%]; transdermal: 5.8% [95% CI: 4.2% to 7.9%]). Signs of opioid addiction were reported in 0.27% of participants in the studies that reported that outcome. All three modes of administration were associated with clinically significant reductions in pain, but the amount of pain relief varied among studies. Findings regarding quality of life and functional status were inconclusive due to an insufficient quantity of evidence for oral administration studies and inconclusive statistical findings for transdermal and intrathecal administration studies. Many patients discontinue long-term opioid therapy (especially oral opioids) due to adverse events or insufficient pain relief; however, weak evidence suggests that patients who are able to continue opioids long-term experience clinically significant pain relief. Whether quality of life or functioning improves is inconclusive. Many minor adverse events (like nausea and headache) occurred, but serious adverse events, including iatrogenic opioid addiction, were rare.", "rating_type": "pairwise", "references": ["The findings of this systematic review suggest that proper management of a type of strong painkiller (opioids) in well-selected patients with no history of substance addiction or abuse can lead to long-term pain relief for some patients with a very small (though not zero) risk of developing addiction, abuse, or other serious side effects. However, the evidence supporting these conclusions is weak, and longer-term studies are needed to identify the patients who are most likely to benefit from treatment."], "simplification1": "We found 26 studies with 27 treatment groups that enrolled a total of 4893 participants. Twenty-five of the studies were case series or uncontrolled long-term trial continuations, the other was an RCT comparing two opioids. Opioids were administered orally (number of study treatments groups [abbreviated as \"k\"] = 12, n = 3040), transdermally, or intrathecally. Many participants discontinued due to adverse effects (oral: 22.9% [95% confidence interval (CI): 15.3% to 32.8%]; transdermal: 12.1% [ 95% CI: 4% to 27.0%]; and intrathecal: 8.9%). Many participants stopped taking opioids because of side effects or insufficient pain relief, but the amount of pain relief varied among studies. Findings regarding quality of life and functional status were inconclusive due to an insufficient quantity of evidence for oral administration studies and inconclusive statistical findings for intrathecular studies. All three modes of administration were associated with clinically significant reductions in pain, but how much pain relief is clinically significant depends on the type of study. Many minor side effects (like nausea and headache) occurred, but serious side effects, including iatrogenic opioid addiction, were rare. Signs of opioid addiction were reported in 0.27% of participants in the studies that reported that outcome.", "simplification2": "We looked at 26 studies with 4893 participants and 27 treatment groups. Most studies were case series or uncontrolled trials, with one being a randomized controlled trial. Opioids were given orally, transdermally, or intrathecally. Many participants stopped due to side effects or not enough pain relief. Only 0.27% showed signs of addiction. All three methods reduced pain, but results varied. Quality of life and function findings were unclear. Many patients stopped long-term opioid use due to side effects or insufficient pain relief, but those who continued experienced significant pain relief. It's unclear if quality of life", "system1": "bart-xsum", "system2": "GPT-4", "ratings": [{"name": "readability", "type": "binary", "value": [1, 1, 1], "agg_value": 1, "agg_strategy": "majority"}]}
{"original": "We reviewed 26 studies with 27 treatment groups that enrolled a total of 4893 participants. Twenty five of the studies were case series or uncontrolled long-term trial continuations, the other was an RCT comparing two opioids. Opioids were administered orally (number of study treatments groups [abbreviated as \"k\"] = 12, n = 3040), transdermally (k = 5, n = 1628), or intrathecally (k = 10, n = 231). Many participants discontinued due to adverse effects (oral: 22.9% [95% confidence interval (CI): 15.3% to 32.8%]; transdermal: 12.1% [95% CI: 4.9% to 27.0%]; intrathecal: 8.9% [95% CI: 4.0% to 26.1%]); or insufficient pain relief (oral: 10.3% [95% CI: 7.6% to 13.9%]; intrathecal: 7.6% [95% CI: 3.7% to 14.8%]; transdermal: 5.8% [95% CI: 4.2% to 7.9%]). Signs of opioid addiction were reported in 0.27% of participants in the studies that reported that outcome. All three modes of administration were associated with clinically significant reductions in pain, but the amount of pain relief varied among studies. Findings regarding quality of life and functional status were inconclusive due to an insufficient quantity of evidence for oral administration studies and inconclusive statistical findings for transdermal and intrathecal administration studies. Many patients discontinue long-term opioid therapy (especially oral opioids) due to adverse events or insufficient pain relief; however, weak evidence suggests that patients who are able to continue opioids long-term experience clinically significant pain relief. Whether quality of life or functioning improves is inconclusive. Many minor adverse events (like nausea and headache) occurred, but serious adverse events, including iatrogenic opioid addiction, were rare.", "rating_type": "pairwise", "references": ["The findings of this systematic review suggest that proper management of a type of strong painkiller (opioids) in well-selected patients with no history of substance addiction or abuse can lead to long-term pain relief for some patients with a very small (though not zero) risk of developing addiction, abuse, or other serious side effects. However, the evidence supporting these conclusions is weak, and longer-term studies are needed to identify the patients who are most likely to benefit from treatment."], "simplification1": "We found 26 studies with 27 treatment groups that enrolled a total of 4893 participants. Twenty-five of the studies were case series or uncontrolled long-term trial continuations, the other was an RCT comparing two opioids. Opioids were administered orally (number of study treatments groups [abbreviated as \"k\"] = 12, n = 3040), transdermally, or intrathecally. Many participants discontinued due to adverse effects (oral: 22.9% [95% confidence interval (CI): 15.3% to 32.8%]; transdermal: 12.1% [ 95% CI: 4% to 27.0%]; and intrathecal: 8.9%). Many participants stopped taking opioids because of side effects or insufficient pain relief, but the amount of pain relief varied among studies. Findings regarding quality of life and functional status were inconclusive due to an insufficient quantity of evidence for oral administration studies and inconclusive statistical findings for intrathecular studies. All three modes of administration were associated with clinically significant reductions in pain, but how much pain relief is clinically significant depends on the type of study. Many minor side effects (like nausea and headache) occurred, but serious side effects, including iatrogenic opioid addiction, were rare. Signs of opioid addiction were reported in 0.27% of participants in the studies that reported that outcome.", "simplification2": "We found 26 studies with a total of 4893 participants. Twenty five of the studies were case series or uncontrolled long-term trial continuations, the other was an RCT (RCT) that compared two different opioids. Opioids (oral, transderm, and intrathecals) were given by mouth, through a vein, or through a skin patch. The studies were conducted in the USA, Canada, and Italy. The average duration of the treatment was six months. The majority of the participants were men. The evidence is current to January 2015. Many participants discontinued long-lasting opioid therapy due to side effects (oral: 22.9% [95% confidence interval (CI) 15.3% to 32.8%]; transdermal: 12.1% [CI: 4.9%) to 27.0%]; intrathecal: 8.9%, [CI] 4.0%) to 26.1%. Many participants stopped taking opioids because of side effects, but the evidence suggests that patients who are able to continue opioids long-time experience clinically significant pain relief. Whether quality of life or functioning improves is inconclusive. Many minor side effects occurred, but serious side effects including opioid addiction were rare. The quality of the evidence was weak due to the small number of studies and participants.", "system1": "bart-xsum", "system2": "Decoder", "ratings": [{"name": "readability", "type": "binary", "value": [0, 0, 0], "agg_value": 0, "agg_strategy": "majority"}]}
{"original": "We reviewed 26 studies with 27 treatment groups that enrolled a total of 4893 participants. Twenty five of the studies were case series or uncontrolled long-term trial continuations, the other was an RCT comparing two opioids. Opioids were administered orally (number of study treatments groups [abbreviated as \"k\"] = 12, n = 3040), transdermally (k = 5, n = 1628), or intrathecally (k = 10, n = 231). Many participants discontinued due to adverse effects (oral: 22.9% [95% confidence interval (CI): 15.3% to 32.8%]; transdermal: 12.1% [95% CI: 4.9% to 27.0%]; intrathecal: 8.9% [95% CI: 4.0% to 26.1%]); or insufficient pain relief (oral: 10.3% [95% CI: 7.6% to 13.9%]; intrathecal: 7.6% [95% CI: 3.7% to 14.8%]; transdermal: 5.8% [95% CI: 4.2% to 7.9%]). Signs of opioid addiction were reported in 0.27% of participants in the studies that reported that outcome. All three modes of administration were associated with clinically significant reductions in pain, but the amount of pain relief varied among studies. Findings regarding quality of life and functional status were inconclusive due to an insufficient quantity of evidence for oral administration studies and inconclusive statistical findings for transdermal and intrathecal administration studies. Many patients discontinue long-term opioid therapy (especially oral opioids) due to adverse events or insufficient pain relief; however, weak evidence suggests that patients who are able to continue opioids long-term experience clinically significant pain relief. Whether quality of life or functioning improves is inconclusive. Many minor adverse events (like nausea and headache) occurred, but serious adverse events, including iatrogenic opioid addiction, were rare.", "rating_type": "pairwise", "references": ["The findings of this systematic review suggest that proper management of a type of strong painkiller (opioids) in well-selected patients with no history of substance addiction or abuse can lead to long-term pain relief for some patients with a very small (though not zero) risk of developing addiction, abuse, or other serious side effects. However, the evidence supporting these conclusions is weak, and longer-term studies are needed to identify the patients who are most likely to benefit from treatment."], "simplification1": "We found 26 studies with 27 treatment groups that enrolled a total of 4893 participants. Twenty-five of the studies were case series or uncontrolled long-term trial continuations, the other was an RCT comparing two opioids. Opioids were administered orally (number of study treatments groups [abbreviated as \"k\"] = 12, n = 3040), transdermally, or intrathecally. Many participants discontinued due to adverse effects (oral: 22.9% [95% confidence interval (CI): 15.3% to 32.8%]; transdermal: 12.1% [ 95% CI: 4% to 27.0%]; and intrathecal: 8.9%). Many participants stopped taking opioids because of side effects or insufficient pain relief, but the amount of pain relief varied among studies. Findings regarding quality of life and functional status were inconclusive due to an insufficient quantity of evidence for oral administration studies and inconclusive statistical findings for intrathecular studies. All three modes of administration were associated with clinically significant reductions in pain, but how much pain relief is clinically significant depends on the type of study. Many minor side effects (like nausea and headache) occurred, but serious side effects, including iatrogenic opioid addiction, were rare. Signs of opioid addiction were reported in 0.27% of participants in the studies that reported that outcome.", "simplification2": "We found 26 studies with a total of 4893 participants. Most studies (22 out of 27) looked at the use of oral (oral) or transdermally (intracathecal) opioids, and one looked at transdermal (intraathecally) analgesics (transdermal analgesics). All three modes of administration reduced the amount of pain that participants felt. However, many patients stopped taking the drugs due to side-effects (like nausea and headache) or because they were too painful. Many of these patients were not able to take the drugs long-term due to adverse events (like rash). However, patients who are able to be able to stay on the painkillers for the rest of their life will have much less pain than if they are not allowed to take them. Whether they will have more pain than they need to be on painkillers and whether they will improve their quality of life or function is not clear. We did not find any studies that looked at opioid use for more than three months. We do not know if people who use opioids for pain relief in the short-term are more or less likely to be dependent on them for their pain relief.", "system1": "bart-xsum", "system2": "UL", "ratings": [{"name": "readability", "type": "binary", "value": [0, 1, 0], "agg_value": 0, "agg_strategy": "majority"}]}
{"original": "We reviewed 26 studies with 27 treatment groups that enrolled a total of 4893 participants. Twenty five of the studies were case series or uncontrolled long-term trial continuations, the other was an RCT comparing two opioids. Opioids were administered orally (number of study treatments groups [abbreviated as \"k\"] = 12, n = 3040), transdermally (k = 5, n = 1628), or intrathecally (k = 10, n = 231). Many participants discontinued due to adverse effects (oral: 22.9% [95% confidence interval (CI): 15.3% to 32.8%]; transdermal: 12.1% [95% CI: 4.9% to 27.0%]; intrathecal: 8.9% [95% CI: 4.0% to 26.1%]); or insufficient pain relief (oral: 10.3% [95% CI: 7.6% to 13.9%]; intrathecal: 7.6% [95% CI: 3.7% to 14.8%]; transdermal: 5.8% [95% CI: 4.2% to 7.9%]). Signs of opioid addiction were reported in 0.27% of participants in the studies that reported that outcome. All three modes of administration were associated with clinically significant reductions in pain, but the amount of pain relief varied among studies. Findings regarding quality of life and functional status were inconclusive due to an insufficient quantity of evidence for oral administration studies and inconclusive statistical findings for transdermal and intrathecal administration studies. Many patients discontinue long-term opioid therapy (especially oral opioids) due to adverse events or insufficient pain relief; however, weak evidence suggests that patients who are able to continue opioids long-term experience clinically significant pain relief. Whether quality of life or functioning improves is inconclusive. Many minor adverse events (like nausea and headache) occurred, but serious adverse events, including iatrogenic opioid addiction, were rare.", "rating_type": "pairwise", "references": ["The findings of this systematic review suggest that proper management of a type of strong painkiller (opioids) in well-selected patients with no history of substance addiction or abuse can lead to long-term pain relief for some patients with a very small (though not zero) risk of developing addiction, abuse, or other serious side effects. However, the evidence supporting these conclusions is weak, and longer-term studies are needed to identify the patients who are most likely to benefit from treatment."], "simplification1": "We found 26 studies with 27 treatment groups that enrolled a total of 4893 participants. Twenty-five of the studies were case series or uncontrolled long-term trial continuations, the other was an RCT comparing two opioids. Opioids were administered orally (number of study treatments groups [abbreviated as \"k\"] = 12, n = 3040), transdermally, or intrathecally. Many participants discontinued due to adverse effects (oral: 22.9% [95% confidence interval (CI): 15.3% to 32.8%]; transdermal: 12.1% [ 95% CI: 4% to 27.0%]; and intrathecal: 8.9%). Many participants stopped taking opioids because of side effects or insufficient pain relief, but the amount of pain relief varied among studies. Findings regarding quality of life and functional status were inconclusive due to an insufficient quantity of evidence for oral administration studies and inconclusive statistical findings for intrathecular studies. All three modes of administration were associated with clinically significant reductions in pain, but how much pain relief is clinically significant depends on the type of study. Many minor side effects (like nausea and headache) occurred, but serious side effects, including iatrogenic opioid addiction, were rare. Signs of opioid addiction were reported in 0.27% of participants in the studies that reported that outcome.", "simplification2": "We included 26 studies with 27 treatment groups that enrolled a total of 4893 participants. Twenty five of the studies were case series or uncontrolled long-term trial continuations, the other was an RCT comparing two opioids. Opioids were administered orally, transdermally, or intrathecally. All three modes of administration were associated with clinically significant reductions in pain, but the amount of pain relief varied among studies. Many participants discontinued due to adverse effects or insufficient pain relief. Many minor adverse events (like nausea and headache) occurred, but serious adverse events, including iatrogenic opioid addiction, were rare. Signs of opioid addiction were reported in 0.27% of participants in the studies that reported that outcome. Findings regarding quality of life and functional status were inconclusive due to an insufficient quantity of evidence for oral administration studies and inconclusive statistical findings for transdermal and intrathecal administration studies. However, weak evidence suggests that patients who are able to continue opioid therapy for a long period of time experience clinically significant pain relief; however, the quality of the evidence is inconclusive.", "system1": "bart-xsum", "system2": "NAPSS", "ratings": [{"name": "readability", "type": "binary", "value": [1, 1, 1], "agg_value": 1, "agg_strategy": "majority"}]}
